NCT01609543View on ClinicalTrials.gov

A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG

erlotinib [Tarceva]

150 mg orally daily, until disease progression, unacceptable toxicity or withdrawal due to any reason

Trial Locations (23)

1125

Budapest

1529

Budapest

2045

Törökbálint

3233

Mátraháza

4032

Debrecen

4400

Nyíregyháza

5004

Szolnok

5703

Gyula

6772

Deszk

7100

Szekszárd

7623

Pécs

8001

Székesfehérvár

8582

Farkasgyepű

9200

Mosonmagyaróvar

9700

Szombathely

22030

Edirne

34890

Istanbul

H-2045

Törökbálint

LV 1079

Riga

LV-1002

Riga

06230

Ankara

06280

Ankara

07070

Antalya

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01609543 - A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations | Biotech Hunter | Biotech Hunter